Resistance to First-Line Osimertinib in EGFR-mutant NSCLC: Tissue is the Issue

Resistance to First-Line Osimertinib in EGFR-mutant NSCLC: Tissue is the Issue:

Matched pre-/post-treatment tissue biopsies from EGFR-mutant NSCLC patients demonstrate that histologic transformations, including both SCLC and squamous transformation, are unexpectedly common among patients progressing on first-line osimertinib. The study highlights the key role of tissue testing and underscores the need for innovative therapeutic approaches to prevent, rather than treat, resistance.